New Imaging-Enhanced CAR T-Cell therapy targets Hard-to-Treat lymphoma
NCT ID NCT07343934
First seen Jan 26, 2026 · Last updated Jun 04, 2026 · Updated 20 times
Summary
This early-phase study tests a new type of CAR T-cell therapy (huCART19-IL18-eDHFR) in 6 adults with follicular lymphoma that has returned or not responded to at least two prior treatments. The therapy uses a special imaging tag to track the cells in the body via PET/CT scans. The main goals are to check safety and see if the cells can be detected, while also looking at how well they work against the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.